Compare Inovio Pharmaceuticals Inc (INO) vs Riot Platforms Inc (RIOT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Riot Platforms Inc — how do they compare? Inovio Pharmaceuticals Inc trades at $1.08 (market cap $90.50M), while Riot Platforms Inc trades at $23.35 (market cap $8.12B). The key difference: Riot Platforms Inc is far larger — about 89.7× Inovio Pharmaceuticals Inc's market cap, and Riot Platforms Inc is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| INO | RIOT | |
|---|---|---|
Market Cap | $90.50M | $8.12B |
Sector | Health | Technology |
52-Week High | $2.87 | $28.67 |
52-Week Low | $1.05 | $11.03 |
Enterprise Value | $61.51M | $8.79B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.10, down 1.79% recently, with a bearish technical signal from moving averages. The company shows minimal revenue of $65,340 in 2025 and a net loss of $84.95 million, resulting in negative profitability margins. Recent news highlights an ongoing FDA review for INO-3107 with a PDUFA date of October 30, 2026, while shareholder litigation investigations emerge. Cash flow remains negative, though operating expenses have declined.
The investment case hinges on the binary FDA decision for INO-3107, offering potential upside if approved, but carries high risk due to persistent losses, negative cash flow, and legal scrutiny. Analyst consensus is moderately bullish with 53% buy ratings, but fundamental weaknesses and technical bearishness suggest cautious positioning is warranted.
RIOT trades at $19.90, up 8.98% in the past 24 hours, but faces a bearish technical signal despite strong analyst support. The company reported a significant net loss of $663.18 million in 2025 with negative profit margins, though revenue reached $647.44 million. Recent news highlights volatility and strategic partnerships in data center development.
Wall Street remains overwhelmingly bullish with 94% buy ratings and a $28.67 price target, but fundamental weaknesses and cash flow challenges present substantial risks. The stock's outlook depends on improving profitability and successful execution of its business expansion amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Riot Platforms Inc
Riot Platforms, Inc. is a Bitcoin mining company that focuses on building, operating, and expanding large-scale infrastructure for digital asset mining in North America. The company's operations include Bitcoin mining, data center hosting, and engineering solutions. Riot's strategy emphasizes vertical integration to maximize efficiency and scale its mining capacity, aiming to be a leader in the global Bitcoin and digital infrastructure industry.
Read more on RIOT →
